A study has upended a long-held view of lacunar strokes, pointing not to fatty blockages but to widening arteries in the brain as a likely cause.

Researchers say the finding could help explain a stubborn clinical puzzle: why some medications do not work well for this common form of stroke. Lacunar strokes account for about a quarter of all strokes in the UK and affect roughly 35,000 people each year, according to the report. For years, doctors had linked them to small arteries clogged by fatty deposits. This new work suggests the damage may start in a different way.

Key Facts

  • Lacunar strokes affect about 35,000 people a year in the UK.
  • They account for roughly one in four strokes in the UK.
  • The study suggests widening of brain arteries, not fatty blockage, drives these strokes.
  • The finding may explain why some medications show limited benefit.

If that conclusion holds up, it would mark more than a technical shift in stroke science. It would force a rethink of how doctors target prevention and treatment. A disease caused by widening vessels may not respond to therapies designed to clear or prevent buildup in narrowed arteries. That gap between cause and treatment may sit at the heart of why some patients see limited benefit.

The new research suggests lacunar strokes may arise from widening arteries in the brain, not the fatty narrowing many experts had long suspected.

The implications stretch beyond the lab. Lacunar strokes often receive less public attention than larger, more dramatic strokes, but they make up a major share of the total burden. Reports indicate this new explanation could sharpen diagnosis and push researchers to test different drugs or prevention strategies. It also gives patients and clinicians a clearer framework for understanding why older assumptions may not match real-world outcomes.

What happens next matters. Researchers will need to confirm the findings and show how they should change care in practice. If future studies support this view, treatment guidelines and drug development could shift toward the underlying changes in small brain arteries rather than the usual model of fatty blockage. For thousands of patients each year, that would not just refine the science — it could finally point to therapies built for the stroke they actually have.